Efficacy and Safety of Recombinant Human Brain Natriuretic Peptide Combined with Nicorandil in the Treatment of Acute Heart Failure
Objective:To observe the efficacy and safety of Recombinant Human Brain Natriuretic Peptide combined with Nicorandil in the treatment of acute heart failure.Method:A total of 100 patients with acute heart failure treated in Yizheng People's Hospital from March 2021 to October 2022 were selected and divided into case group and control group by random number table method,with 50 patients in each group.The control group was treated with Recombinant Human Brain Natriuretic Peptide,and the case group was treated with Nicorandil on the basis of the control group.The clinical efficacy,left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),N-terminal pro-brain natriuretic peptide(NT-proBNP),cardiac troponin I(cTnI)and C-reactive protein(CRP)levels before and after treatment were compared between the two groups,and the incidence of adverse reactions was recorded.Result:The total effective rate of the case group was 94.00%,which was higher than 80.00%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in serum NT-proBNP,cTnI and CRP between the two groups(P>0.05).After treatment,serum NT-proBNP,cTnI and CRP in two groups were lower than those before treatment,and which in the case group were lower than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in LVEF and LVEDD between the two groups(P>0.05).After treatment,LVEF and LVEDD in both groups were better than those before treatment,and which in the case group were better than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Recombinant Human Brain Natriuretic Peptide combined with Nicorandil has a significant effect in the treatment of patients with acute heart failure,which can reduce the levels of serum cTnI,NT-proBNP and CRP in patients with acute heart failure,improve the cardiac function of patients with acute heart failure,and is safe and reliable.
NicorandilRecombinant Human Brain Natriuretic PeptideAcute heart failureSecurityLeft ventricular end-diastolic diameterLeft ventricular ejection fractionSerum N-terminal pro-brain natriuretic peptideCardiac troponin I
万方数据
维普
